Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UB 312 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors United Neuroscience

Most Recent Events

20 Jun 2024 According to a Vaxxinity media release, results form this trial were published in the Nature Medicine.
20 Jun 2024 Results presented in the Vaxxinity Media Release.
18 Apr 2024 Results assessing whether target engagement can be demonstrated in CSF samples of Parkinsons disease patients immunized with UB-312 presented at the 76th Annual Meeting of the American Academy of Neurology 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com